A0A6D2X694 (A0A6D2X694_PANTR) Pan troglodytes (Chimpanzee)

SFN isoform 1 UniProtKBInterProInteractive Modelling

248 aa; Sequence (Fasta) ; 5 identical sequences: Homo sapiens: P31947; Pan troglodytes: H2RC87; Pan paniscus: A0A2R8ZKA8; Gorilla gorilla gorilla: G3R777; Nomascus leucogenys: G1SAD1

Available Structures

449 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) Heteromer
P04049; P31947;
1-231
100CL;MG;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1014 Heteromer
P31947; Q13526;
1-231
100.0SFW;CA;CL;
Co-soaked stabilizers for ERa - 14-3-3 interaction (884_AZ354) Heteromer
P03372; P31947;
1-231
99.13MG;GEH;LF5;
Co-soaked stabilizers for ERa - 14-3-3 interaction (844_AZ210) Heteromer
P03372; P31947;
1-231
99.13MG;SSX;GEH;
co-soaked stabilizers for ERa - 14-3-3 interaction (884_AZ244) Heteromer
P03372; P31947;
1-231
99.13MG;GEH;SG0;
Cys-42-tethered stabilizer 12 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T5Z;
14-3-3 sigma sirtuin-3 phospho-peptide complex Heteromer
P31947; Q9NTG7;
1-231
100MG;CA;CL;
14-3-3 sigma in complex with IkappaBalpha pS63 peptide Heteromer
P25963; P31947;
1-231
100CA;CL;MG; 14×GOL;
14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005 Heteromer
P31947; Q04206;
1-231
100CL;0V4;
14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CL;NA;
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (10mer) Heteromer
P04049; P31947;
1-231
100CL;MG;
14-3-3 sigma in complex with YAP pS127-peptide Heteromer
P31947; P46937;
1-231
100MG;CL;CA;GOL;
Cys-45-tethered stabilizer 4 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T4Q;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1013 Heteromer
P31947; Q13526;
1-231
100.0SGH;CA;CL;
Cys-45-tethered stabilizer 5 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T4Z;
Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide Heteromer
P03372; P31947;
1-231
100.0
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) and stabilisator Fusico… Heteromer
P04049; P31947;
1-231
100FSC;CL;MG;
Small molecular stabilizer for ERalpha and 14-3-3 (1083744) Heteromer
P03372; P31947;
1-231
100MG;NJ3;
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C45 mutant bound to disulfide f… Heteromer
P03372; P31947;
1-231
99.13MG;GE8;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074361) Heteromer
P03372; P31947;
1-231
100MG;S0O;
Cys-42-tethered stabilizer 10 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T6H;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074361) Heteromer
P03372; P31947;
1-231
100MG;U0L;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074372) Heteromer
P03372; P31947;
1-231
100MG;RZL;
14-3-3 sigma bound to bis-phosphorylated aminopeptidase N (APN, CD13) via canonical and non-canonic… Heteromer
P15144; P31947;
1-231
100NA;CL;
14-3-3 sigma with RelA/p65 binding site pS45 Heteromer
P31947; Q04206;
1-231
100GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043 Heteromer
P31947; Q04206;
1-231
100.0V0Q;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192 Heteromer
P31947; Q04206;
1-231
100.0V2N;V2K;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046 Heteromer
P31947; Q04206;
1-231
100.0CL;V0T;CA;GOL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180 Heteromer
P31947; Q04206;
1-231
100.0TVB;CA;CL;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187 Heteromer
P31947; Q04206;
1-231
100.0TW8;CA;CL;PEG;
Fragment AZ-003 binding at the TAZpS89/14-3-3 sigma interface Heteromer
P31947; Q9GZV5;
1-231
100.0MG;CL;K48;
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide Heteromer
P04637; P31947;
1-231
100.0CA;MG;
14-3-3sigma covalently bound to peptide (chloroacetamide-Cys interaction) Heteromer
P31947; P46937;
1-231
100.0MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185 Heteromer
P31947; Q04206;
1-231
100.0UT8;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184 Heteromer
P31947; Q04206;
1-231
100.0UVK;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182 Heteromer
P31947; Q04206;
1-231
100.0UVZ;CL;MG;PEG;
14-3-3 sigma in complex with TAZ peptide and stabilizing fragment TCF199 Heteromer
P31947; Q9GZV5;
1-231
100.0XJF;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188 Heteromer
P31947; Q04206;
1-231
100.0UST;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183 Heteromer
P31947; Q04206;
1-231
100.0UVE;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179 Heteromer
P31947; Q04206;
1-231
100.0TQW;GOL;CA;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181 Heteromer
P31947; Q04206;
1-231
100.0UVQ;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186 Heteromer
P31947; Q04206;
1-231
100.0USW;CL;MG;PEG;
single soak stabilizer for ERa - 14-3-3 interaction (AZ275) Heteromer
P03372; P31947;
1-231
100MG;SDM;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521 Heteromer
P31947; Q04206;
1-231
100.0L3Y;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009 Heteromer
P31947; Q04206;
1-231
100.0TJ8;MG;
14-3-3 sigma with RelA/p65 binding site pS281 Heteromer
P31947; Q04206;
1-231
100
14-3-3sigma in complex with a S131beta3S mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CL;MG;NA;
single soak stabilizer for ERa - 14-3-3 interaction (AZ555) Heteromer
P03372; P31947;
1-231
100MG;L1T;
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2e-I with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0NA;D3W;CL;
Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide Heteromer
P31947; Q4VCS5;
1-231
100MG;CL;
Fragment AZ-018 binding at the TAZpS89/14-3-3 sigma interface Heteromer
P31947; Q9GZV5;
1-231
100K5Z;
Binary complex of 14-3-3 sigma and p53 pT387-peptide Heteromer
P04637; P31947;
1-231
100.0MG;CL;GOL;
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… Heteromer
P31947; P62508;
1-231
99.57MG;CL;O68;
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… Heteromer
P31947; P62508;
1-231
99.57MG;CL;O3W;
Cys-42-tethered stabilizer 13 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T6W;
single soak stabilizer for ERa - 14-3-3 interaction (AZ354) Heteromer
P03372; P31947;
1-231
100MG;LF5;
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… Heteromer
P31947; P62508;
1-231
99.57MG;CL;O4E;
Crystal structure of 14-3-3 sigma in complex with wild-type Shroom3 Heteromer
P31947; Q8TF72;
1-231
100.0MG;CL;
Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;GOL;K48;
14-3-3 sigma in complex with SMAD2 pS465 peptide Heteromer
P31947; Q15796;
1-231
100.010×MG;GOL;CL;CA;NA;
Human 14-3-3 sigma in complex with human MDM2 peptide Heteromer
P31947; Q00987;
1-231
100GOL;PEG;CL;MG;
Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS935 Heteromer
P31947; Q5S007;
1-231
100CA;CL;
14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046 Heteromer
P31947; Q04206;
1-231
100.0UQN;GOL;
Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… Heteromer
P31947; P62508;
1-231
99.57MG;CL;O85;
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ177 Heteromer
P31947; Q4VCS5;
1-231
100.00BS;MG;
Small molecular stabilizer for ERalpha and 14-3-3 (1076394) Heteromer
P03372; P31947;
1-231
100.0MG;NK6;
Small molecule stabilizer (compound 1) for ERalpha and 14-3-3 Heteromer
P03372; P31947;
1-231
100MG;O6C;
14-3-3sigma in complex with a L132beta3L mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CL;MG;NA;
Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 22 Heteromer
P31947; Q4VCS5;
1-231
100.0K92;CA;CL;MG;
14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV3 Heteromer
P31947; Q9GZV5;
1-231
100.0MG;CL;CA;8OE;
Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 09 Heteromer
P31947; Q4VCS5;
1-231
100K7N;CA;CL;
Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (DBD) phosphopeptide Heteromer
P31947; P62508;
1-231
99.57MG;CL;
Small molecular stabilizer for ERalpha and 14-3-3 (1075311) Heteromer
P03372; P31947;
1-231
100MG;MU9;
Small molecular stabilizer for ERalpha and 14-3-3 (1080299) Heteromer
P03372; P31947;
1-231
100MG;OT0;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069 Heteromer
P31947; Q04206;
1-231
100CL;TZH;
Small molecule amidine soak in 14-3-3/ERa (AZ037) Heteromer
P03372; P31947;
1-231
100MG;TG9;
Small molecule stabilizer (1075481) for ERalpha and 14-3-3 Heteromer
P03372; P31947;
1-231
100MG;O0O;
Small molecular stabilizer for C-RAF (pS259) and 14-3-3 (1075306) Heteromer
P04049; P31947;
1-231
100CL;MG;O5I;
Small molecular stabilizer for ERalpha and 14-3-3 (1080297) Heteromer
P03372; P31947;
1-231
100MG;O3F;
Binary structure of 14-3-3s and PKR phosphopeptide Heteromer
P19525; P31947;
1-231
100MG;
Small molecule stabilizer for ERalpha and 14-3-3 (1075478) Heteromer
P03372; P31947;
1-231
100MG;N0L;
Binary structure of 14-3-3s and RND3 phosphopeptide Heteromer
P31947; P61587;
1-231
99.57MG;CL;
Small molecule stabilizer for ERalpha and 14-3-3 (1080269) Heteromer
P03372; P31947;
1-231
100MG;NUO;
Small molecular stabilizer for ERalpha and 14-3-3sigma (1074378) Heteromer
P03372; P31947;
1-231
100MG;NR6;
Small molecular stabilizer for ERalpha and 14-3-3 (1080267) Heteromer
P03372; P31947;
1-231
100MG;NF9;
fragment-linked stabilizer for ERa - 14-3-3 interaction (AZ210) Heteromer
P03372; P31947;
1-231
100MG;SD7;
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide Heteromer
P31947; Q9NPC2;
1-231
100MG;CL;
Cys-42-tethered stabilizer 8 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T5Q;
Ternary structure of 14-3-3s, RND3 phosphopeptide and dual-reactive compound 10 Heteromer
P31947; P61587;
1-231
99.57MG;CL;OQ3;
small molecule stabilizer for ERalpha and 14-3-3 (1083743) Heteromer
P03372; P31947;
1-231
100MG;NJC;
Ternary structure of 14-3-3sigma, PKA-responsive ERa phosphopeptide and Fusicoccin-A Heteromer
P03372; P31947;
1-231
100MG;SIT;
Small molecular stabilizer for ERalpha and 14-3-3 (1080265) Heteromer
P03372; P31947;
1-231
100MG;NJI;
Cys-42-tethered stabilizer 6 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T5N;
Small molecular stabilizer for ERalpha and 14-3-3 (1080272) Heteromer
P03372; P31947;
1-231
100MG;MVU;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111 Heteromer
P31947; Q04206;
1-231
100.0UON;UOT;PEG;CL;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134 Heteromer
P31947; Q04206;
1-231
100.0UVH;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135 Heteromer
P31947; Q04206;
1-231
100.0UHQ;GOL;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154 Heteromer
P31947; Q04206;
1-231
100.0TZW;
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ180 Heteromer
P31947; Q4VCS5;
1-231
100.00BL;CL;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131 Heteromer
P31947; Q04206;
1-231
100.0UVB;MG;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118 Heteromer
P31947; Q04206;
1-231
100.0CL;GOL;UHW;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125 Heteromer
P31947; Q04206;
1-231
100.0UWH;CA;CL;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124 Heteromer
P31947; Q04206;
1-231
100.0UGN;CA;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119 Heteromer
P31947; Q04206;
1-231
100.0CL;CA;UHT;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142 Heteromer
P31947; Q04206;
1-231
100.0TWQ;
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ162 Heteromer
P31947; Q4VCS5;
1-231
100.009W;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117 Heteromer
P31947; Q04206;
1-231
100.0V0W;CL;MG;GOL;
Crystal structure of 14-3-3 in complex with PyrinpS242 and a protein/peptide interface fragment Heteromer
O15553; P31947;
1-231
100.0463;PE5;MG;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116 Heteromer
P31947; Q04206;
1-231
100.0CL;CA;GOL;PEG;V1K;
14-3-3 sigma in complex with Pin1 binding site pS72 and covalently bound TCF521-026 Heteromer
P31947; Q13526;
1-231
100.0S6B;CA;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130 Heteromer
P31947; Q04206;
1-231
100.0UVN;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120 Heteromer
P31947; Q04206;
1-231
100.0UXN;CL;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2046 Heteromer
P31947; Q13526;
1-231
100.0TKK;CA;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128 Heteromer
P31947; Q04206;
1-231
100.0UGQ;CL;CA;GOL;
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 09 Heteromer
P31947; Q4VCS5;
1-231
100.0CL;MG;K7N;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083 Heteromer
P31947; Q04206;
1-231
100.0V48;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097 Heteromer
P31947; Q04206;
1-231
100.0V42;CA;CL;
Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif II Heteromer
P31947; Q6TGC4;
1-231
100.0MG;
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-I with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0NA;D3Q;CL;
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2c-I with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0CL;MG;NA;D3K;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133 Heteromer
P31947; Q04206;
1-231
100.0UGE;PEG;
Crystal structure of C-terminal modified Tau peptide-hybrid 126B with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080 Heteromer
P31947; Q04206;
1-231
100.0V4N;CL;CA;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096 Heteromer
P31947; Q04206;
1-231
100.0V3Z;CL;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127 Heteromer
P31947; Q04206;
1-231
100.0UVT;CL;MG;GOL;
Small molecule stabilizer for ERalpha and 14-3-3 (1074359) Heteromer
P03372; P31947;
1-231
100MG;N1R;
Small molecular stabilizer for ERalpha and 14-3-3 (1080266) Heteromer
P03372; P31947;
1-231
100MG;NKL;
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 7 Heteromer
P31947; P62508;
1-231
99.57MG;CL;QQ0;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1075302) Heteromer
P03372; P31947;
1-231
100MG;SOI;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126 Heteromer
P31947; Q04206;
1-231
100.0UHN;CA;CL;
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 8 Heteromer
P31947; P62508;
1-231
99.57MG;CL;QL0;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129 Heteromer
P31947; Q04206;
1-231
100.0P7T;
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 5 Heteromer
P31947; P62508;
1-231
99.57MG;CL;OYI;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070 Heteromer
P31947; Q04206;
1-231
100.0GOL;CA;UHZ;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153 Heteromer
P31947; Q04206;
1-231
100.0U1B;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157 Heteromer
P31947; Q04206;
1-231
100.0V2E;
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 6 Heteromer
P31947; P62508;
1-231
99.56MG;CL;QL9;
Small molecular stabilizer for ERalpha and 14-3-3 (1074202 - non covalent) Heteromer
P03372; P31947;
1-231
100MG;O4I;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132 Heteromer
P31947; Q04206;
1-231
100.0GOL;CL;UG8;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123 Heteromer
P31947; Q04206;
1-231
100P7E;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121 Heteromer
P31947; Q04206;
1-231
100.0UWK;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122 Heteromer
P31947; Q04206;
1-231
100.0UWQ;CA;
14-3-3 Sigma in complex with phosphorylated MLF1 peptide Heteromer
P31947; P58340;
1-231
100.0CA;MG;CL;
FC-J stabilizer for ERa and 14-3-3 Heteromer
P03372; P31947;
1-231
100MG;SIY;
Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ178 Heteromer
P03372; P31947;
1-231
100.0MG;CL;0B7;
A novel phospho-switch in the linker region of the snail zinc finger protein which regulates 14-3-3… Heteromer
O95863; P31947;
1-231
99.57MG;GOL;
Cys-42-tethered stabilizer 9 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T5W;
Small molecular stabilizer for ERalpha and 14-3-3 (1080273) Heteromer
P03372; P31947;
1-231
100MG;NQU;
Cys-42-tethered stabilizer 7 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T5T;
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-II with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0CL;NA;D4K;
Crystal structure of 14-3-3 sigma in complex with Shroom3 P1244L Heteromer
P31947; Q8TF72;
1-231
100.0MG;CL;
Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS910 Heteromer
P31947; Q5S007;
1-231
100CA;CL;NA;
Small molecule amidine soak in 14-3-3/ERa (AZ132) Heteromer
P03372; P31947;
1-231
100MG;KM8;
FC-NAc stabilizer of 14-3-3 and ERalpha Heteromer
P03372; P31947;
1-231
100MG;EZ5;
Fragment AZ-010 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0KM8;
14-3-3 in complex with Pyrinp pS242 Heteromer
O15553; P31947;
1-231
100.0
14-3-3sigma in complex with a A130beta3A mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CL;MG;NA;
Cys-42-tethered stabilizer 11 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T6N;
Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide and ligands Fusicoccin-A a… Heteromer
P03372; P31947;
1-231
100.0FSC;UGH;
FC-31 stabilizer of 14-3-3 and ERalpha Heteromer
P03372; P31947;
1-231
100MG;SJC;
14-3-3 Sigma in complex with phosphorylated c-Jun peptide Heteromer
P05412; P31947;
1-231
100.0MG;CA;
small molecule stabilizer (compound 1) for C-RAF pS259 and 14-3-3 Heteromer
P04049; P31947;
1-231
100CL;MG;O6C;
Small molecular stabilizer for ERalpha and 14-3-3 (1076405) Heteromer
P03372; P31947;
1-231
100MG;ND9;
Small molecular stabilizer for ERalpha and 14-3-3 (1075310) Heteromer
P03372; P31947;
1-231
100MG;MVO;
Small molecular stabilizer for ERalpha and 14-3-3 (1076402) Heteromer
P03372; P31947;
1-231
100MG;NQ9;
Small molecule stabilizer for ERalpha and 14-3-3 (1080298) Heteromer
P03372; P31947;
1-231
100MG;O2X;
Small molecule stabilizer for ERalpha and 14-3-3 (1076406) Heteromer
P03372; P31947;
1-231
100MG;NQ0;
14-3-3 Sigma in complex with phosphorylated (Thr391) Gab2 peptide Heteromer
P31947; Q9UQC2;
1-231
100MG;
14-3-3 Sigma in complex with phosphorylated camkk2{pS511} peptide Heteromer
P31947; Q96RR4;
1-231
100MG;CL;
14-3-3 sigma in complex with Pin1 binding site pS72 Heteromer
P31947; Q13526;
1-231
100CA;CL;
Small molecular stabilizer for ERalpha and 14-3-3 (1076397) Heteromer
P03372; P31947;
1-231
100MG;MRF;
deAc-FC stabilizer of 14-3-3 and ERalpha Heteromer
P03372; P31947;
1-231
100MG;SIT;
Small molecular stabilizer for ERalpha and 14-3-3 (1080294) Heteromer
P03372; P31947;
1-231
100MG;NIB;
Small molecular stabilizer for ERalpha and 14-3-3 (1076398) Heteromer
P03372; P31947;
1-231
100MG;NQL;
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ136 Heteromer
P31947; Q4VCS5;
1-231
100.00AW;BME;MG;
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 40 Heteromer
P31947; Q4VCS5;
1-231
100.0UJW;CL;
14-3-3 Sigma in complex with phosphorylated CAMKK2 peptide Heteromer
P31947; Q96RR4;
1-231
100.0MG;CA;
Small molecular stabilizer for ERalpha and 14-3-3 (1080300) Heteromer
P03372; P31947;
1-231
100MG;NG9;
Crystal structure of C-terminal modified Tau peptide-hybrid 4.2b with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0CL;NA;D4H;
14-3-3 Sigma in complex with phosphorylated caspase{pS164} peptide Heteromer
P31947; P42575;
1-231
100.0MG;CL;
14-3-3sigma in complex with SLP76pS376 phosphopeptide crystal structure Heteromer
P31947; Q13094;
1-231
10010×MG;
FC-J acetonide stabilizer of 14-3-3 and ERalpha Heteromer
P03372; P31947;
1-231
100MG;SJ4;
Fragment AZ-009 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0KLZ;MG;
14-3-3 Sigma in complex with phosphorylated caspase{pS139} peptide Heteromer
P31947; P42575;
1-231
100.0MG;CL;
Fragment AZ-015 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;GOL;K6B;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1005 Heteromer
P31947; Q13526;
1-231
100.0UG5;CA;
Small molecular stabilizer for ERalpha and 14-3-3 (1080293) Heteromer
P03372; P31947;
1-231
100MG;O3O;
Small molecule stabilizer (compound 3) for FOXO1 and 14-3-3 Heteromer
P31947; Q12778;
1-231
100MG;L70;
Small molecular stabilizer for ERalpha and 14-3-3 (1080291) Heteromer
P03372; P31947;
1-231
100MG;NJR;
Small molecular stabilizer for ERalpha and 14-3-3sigma (1080268) Heteromer
P03372; P31947;
1-231
100MG;M79;
Small molecule stabilizer for ERalpha and 14-3-3 (1075297) Heteromer
P03372; P31947;
1-231
100MG;O6L;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1075287) Heteromer
P03372; P31947;
1-231
100S1I;
Small molecular stabilizer for ERalpha and 14-3-3 (1080295) Heteromer
P03372; P31947;
1-231
100MG;NE9;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1075296) Heteromer
P03372; P31947;
1-231
100S3U;
Fragment-linked stabilizer for ERa - 14-3-3 interaction (1075293) Heteromer
P03372; P31947;
1-231
100S2E;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074398) Heteromer
P03372; P31947;
1-231
100S8O;
Small molecule stabilizer (compound 7) for C-RAF and 14-3-3 Heteromer
P04049; P31947;
1-231
100CL;MG;L6L;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074397) Heteromer
P03372; P31947;
1-231
100MG;S0U;
Fragment-linked stabilizer for 14-3-3 and ERa (1075298) Heteromer
P03372; P31947;
1-231
100RZT;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074395) Heteromer
P03372; P31947;
1-231
100SE3;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1075316) Heteromer
P03372; P31947;
1-231
100MG;S7R;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074393) Heteromer
P03372; P31947;
1-231
100S3I;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074386) Heteromer
P03372; P31947;
1-231
100RYR;
Small molecule stabilizer (compound 8) for C-RAF and 14-3-3 Heteromer
P04049; P31947;
1-231
100CL;MG;O56;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074399) Heteromer
P03372; P31947;
1-231
100S1R;
fragment-linked stabilizer for ERa - 14-3-3 interactions (1075288) Heteromer
P03372; P31947;
1-231
100S7I;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074392) Heteromer
P03372; P31947;
1-231
100RZC;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1075292) Heteromer
P03372; P31947;
1-231
100S86;
Small molecule stabilizer for ERalpha and 14-3-3 (1075306) Heteromer
P03372; P31947;
1-231
100MG;O5I;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1075313) Heteromer
P03372; P31947;
1-231
100RY0;
Small molecule stabilizer (compound 2) for FOXO1 and 14-3-3 Heteromer
P31947; Q12778;
1-231
100MG;L7L;
14-3-3sigma in complex with a R124beta3R mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CL;MG;NA;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1074388) Heteromer
P03372; P31947;
1-231
100S2U;
Small molecular stabilizer for ERalpha and 14-3-3 (1076403) Heteromer
P03372; P31947;
1-231
100MG;MV3;
Small molecule stabilizer (compound 5) for C-RAF(pS259) and 14-3-3 Heteromer
P04049; P31947;
1-231
100MG;L7U;
Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ162 Heteromer
P03372; P31947;
1-231
100.009W;BME;CL;MG;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound CV1040 Heteromer
P31947; Q13526;
1-231
100.0T85;MG;
Small molecule stabilizer for 14-3-3/ChREBP (Cmd1-soaking) Heteromer
P31947; Q9NP71;
1-231
100.0MG;OQE;
Fragment AZ-024 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;K7Q;
14-3-3 sigma with Pin1 binding site pS72 and bound Fusicoccin A Heteromer
P31947; Q13526;
1-231
100.0FSC;MG;
14-3-3 in complex with PyrinpS208pS242 Heteromer
O15553; P31947;
1-231
100.0B3P;
FC-THF stabilizer of 14-3-3 and ERalpha Heteromer
P03372; P31947;
1-231
100FC7;
Fragment AZ-025 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;K7N;
Fragment AZ-026 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;K92;
Small molecular stabilizer for ERalpha and 14-3-3 (1075305) Heteromer
P03372; P31947;
1-231
100MG;O49;
14-3-3 sigma in complex with SMAD4 pS403 peptide Heteromer
P31947; Q13485;
1-231
100.0GOL;NA;MG;CA;
14-3-3 sigma bound to canonical mono-phosphorylated aminopeptidase N (APN, CD13) binding motif Heteromer
P15144; P31947;
1-231
100NA;CA;MG;
Fragment AZ-011 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;LFB;
Fragment AZ-012 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0CL;LF5;
Fragment AZ-014 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;K6N;
Fragment AZ-017 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;LFQ;
Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide Heteromer
P31947; Q9NQU5;
1-231
100.0CA;CL;MG;NA;
Fragment AZ-020 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0K65;
14-3-3 sigma sirtuin-1 phospho-peptide complex Heteromer
P31947; Q96EB6;
1-231
100.0MG;CL;
FC-NAg stabilizer of 14-3-3 and ERalpha Heteromer
P03372; P31947;
1-231
100MG;SKR;
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer fu… Heteromer
P31947; Q9NPC2;
1-231
99.13FSC;CL;MG;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1047455) Heteromer
P03372; P31947;
1-231
100S6X;
Fragment AZ-002 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0KLE;CA;MG;
Fragment AZ-007 binding at a primary and secondary binding site of the the p53pT387/14-3-3 sigma co… Heteromer
P04637; P31947;
1-231
100.0KLB;CA;MG;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1012 Heteromer
P31947; Q13526;
1-231
100.0TLK;CA;CL;MG;
Fragment AZ-004 binding at a primary and secondary site in a p53pT387/14-3-3 complex Heteromer
P04637; P31947;
1-231
100.0L1T;CA;
Small molecular stabilizer for C-RAF (pS259) and 14-3-3 (1075297) Heteromer
P04049; P31947;
1-231
100CL;MG;O6L;
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 Peptide and stabilizer fu… Heteromer
P31947; Q9NPC2;
1-231
99.13FSC;CL;MG;CA;
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide Heteromer
P31947; Q9NPC2;
1-231
99.13MG;CL;CA;
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… Heteromer
P03372; P31947;
1-231
99.13MG;G8Q;
Cys-45-tethered stabilizer 3 of 14-3-3(sigma)/ERa PPI Heteromer
P03372; P31947;
1-231
99.13MG;T4W;
14-3-3 isoform sigma in complex with a phosphorylated C-RAF peptide Heteromer
P04049; P31947;
1-231
100.0
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110 Heteromer
P31947; Q04206;
1-231
100.0S9E;PEG;
Crystal structure of C-terminal modified Tau peptide-hybrid 3.2d with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0CL;MG;NA;60H;
14-3-3 sigma in complex with SMAD3 pS423 peptide Heteromer
P31947; P84022;
1-231
100.0MG;CL;CA;GOL;NA;
Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS324 Heteromer
P10636; P31947;
1-231
99.55MG;CA;CL;
Crystal structure of C-terminal modified Tau peptide-hybrid 109B with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.049F;
co-soak stabilizers for ERa - 14-3-3 interaction (884_AZ275) Heteromer
P03372; P31947;
1-231
99.57MG;GEH;SDM;
Ternary complex of 14-3-3 sigma, Usp8pS718 phosphopeptide and small molecule stabilizer Heteromer
P31947; P40818;
1-231
100O6C;
fragment-linked stabilizer for ERa - 14-3-3 interaction (1047648) Heteromer
P03372; P31947;
1-231
100S6O;
Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide Heteromer
P31947; Q9Y4G8;
1-231
100.0CA;CL; 10×NA;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-011 Heteromer
P31947; Q13526;
1-231
100.0P5N;CA;CL;
14-3-3 Sigma in complex with phosphorylated SOS1 peptide Heteromer
P31947; Q07889;
1-231
100.0MG;CL;CA;
Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide stabilized by semi-synt… Heteromer
P31947; Q9NQU5;
1-231
100.0HY5;CL;NA;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1019 Heteromer
P31947; Q13526;
1-231
100.0TL8;CA;CL;
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide Heteromer
P31947; Q4VCS5;
1-231
100.0CL;MG;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1006 Heteromer
P31947; Q13526;
1-231
100.0UG2;CL;
14-3-3 Sigma in complex with phosphorylated PLN peptide Heteromer
P26678; P31947;
1-231
100.0MG;CL;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1009 Heteromer
P31947; Q13526;
1-231
100.0TJ8;MG;
14-3-3 sigma in complex with hDM2-186 peptide Heteromer
P31947; Q00987;
1-231
100.0IOD;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1002F1 Heteromer
P31947; Q13526;
1-231
100.0UPQ;CA;CL;PEG;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1017 Heteromer
P31947; Q13526;
1-231
100.0TJB;MG;
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer Fusicoccin H Heteromer
P31947; Q9NPC2;
1-231
100.0MG;CL;GOL;0DV;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-110 Heteromer
P31947; Q13526;
1-231
100.0S9E;CA;
small molecule stabilizer for ERalpha and 14-3-3 (1074202) Heteromer
P03372; P31947;
1-231
100MG;O4I;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044 Heteromer
P31947; Q04206;
1-231
100CL;TZK;GOL;CA;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028 Heteromer
P31947; Q04206;
1-231
100CL;P5Q;
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Fu… Heteromer
P31947; Q9NPC2;
1-231
99.13FJA;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033 Heteromer
P31947; Q04206;
1-231
100CL;P6Z;
Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide and stabilizer Fusicoccin-A Heteromer
P31947; Q86U70;
1-231
100FSC;CL;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037 Heteromer
P31947; Q04206;
1-231
100CL;P6H;
Small molecule stabilizer for 14-3-3/ChREBP (Cmd 30) Heteromer
P31947; Q9NP71;
1-231
100U0U;
Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide Heteromer
P31947; Q86U70;
1-231
100CA;CL;MG;GOL;
Small molecular stabilizer for ERalpha and 14-3-3 (1075299) Heteromer
P03372; P31947;
1-231
100MG;O3T;
Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide Heteromer
P31947; Q9BWG4;
1-231
100MG;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011 Heteromer
P31947; Q04206;
1-231
100CL;P5N;
Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide Heteromer
P06748; P31947;
1-231
100CL;MG;
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Co… Heteromer
P31947; Q9NPC2;
1-231
99.13CX7;MG;
Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide Heteromer
O43353; P31947;
1-231
100CA;MG;
Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide Heteromer
P19525; P31947;
1-231
100MG;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068A Heteromer
P31947; Q13526;
1-231
100.0TKH;CA;CL;
Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ178 Heteromer
P31947; Q99466;
1-231
100.0CL;MG;0B7;
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide Heteromer
P04637; P31947;
1-231
100.0CL;MG;
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ178 Heteromer
P31947; P46527;
1-231
100.00B7;MG;CL;
Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ136 Heteromer
P31947; Q99466;
1-231
100.0CL;MG;0AW;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175 Heteromer
P31947; Q04206;
1-231
100.0CL;TWE;
Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0
Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.049F;
Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ136 Heteromer
P31947; Q13526;
1-231
100.00AW;CL;
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ147 Heteromer
P31947; P46527;
1-231
100.0MG;CL;0I2;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025 Heteromer
P31947; Q04206;
1-231
100.0CL;L3S;
Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ162 Heteromer
P31947; Q13526;
1-231
100.009W;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158 Heteromer
P31947; Q04206;
1-231
100.0CL;V2Q;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1032 Heteromer
P31947; Q13526;
1-231
100.0UPK;GOL;PEG;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161 Heteromer
P31947; Q04206;
1-231
100.0CL;V32;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042 Heteromer
P31947; Q04206;
1-231
100.0CL;V1E;CA;GOL;
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ136 Heteromer
P31947; P46527;
1-231
100.00AW;MG;CL;CA;
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 41 Heteromer
P31947; Q4VCS5;
1-231
100.0K8W;CA;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166 Heteromer
P31947; Q04206;
1-231
100.0CL;V3N;
14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV2 Heteromer
P31947; Q9GZV5;
1-231
100.0MG;CL;8OB;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1007 Heteromer
P31947; Q13526;
1-231
100.0JFS;CA;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176 Heteromer
P31947; Q04206;
1-231
100.0CL;V4H;CA;PEG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164 Heteromer
P31947; Q04206;
1-231
100.0CL;V3B;PEG;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173 Heteromer
P31947; Q04206;
1-231
100.0CL;V3W;CA;PEG;
Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide and stabilizer Fusicoccin-A Heteromer
P19525; P31947;
1-231
100.0FSC;MG;
Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ162 Heteromer
P31947; Q99466;
1-231
100.0CL;09W;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041 Heteromer
P31947; Q04206;
1-231
100.0CL;V1Q;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159 Heteromer
P31947; Q04206;
1-231
100.0CL;V2T;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167 Heteromer
P31947; Q04206;
1-231
100.0CL;V3Q;MG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168 Heteromer
P31947; Q04206;
1-231
100.0CL;V3T;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085 Heteromer
P31947; Q04206;
1-231
100.0CL;V4B;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165 Heteromer
P31947; Q04206;
1-231
100.0CL;V3K;GOL;CA;
Small molecular stabilizer for ERalpha and 14-3-3 (1075300) Heteromer
P03372; P31947;
1-231
100.0MG;O4R;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160 Heteromer
P31947; Q04206;
1-231
100.0CL;V2W;MG;GOL;
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ162 Heteromer
P31947; P46527;
1-231
100.009W;MG;CL;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1016 Heteromer
P31947; Q13526;
1-231
100.0TQK;CA;CL;
Small molecule stabilizer for ERalpha and 14-3-3 (1074210) Heteromer
P03372; P31947;
1-231
100MG;ODC;
Fragment AZ-010 binding at the TAZpS89/14-3-3 sigma interface Heteromer
P31947; Q9GZV5;
1-231
100.0KM8;
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… Heteromer
P03372; P31947;
1-231
99.13MG;G8T;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068B Heteromer
P31947; Q13526;
1-231
100.0TJK;CA;CL;MG;
14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV1 Heteromer
P31947; Q9GZV5;
1-231
100.0MG;CL;NV1;
Crystal structure of 14-3-3 sigma in complex with Ataxin-1 Ser776 phosphopeptide Heteromer
P31947; P54253;
1-231
100MG;CL;
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… Heteromer
P03372; P31947;
1-231
99.13MG;G4Z;
14-3-3 sigma in complex with TAZ pS89 peptide Heteromer
P31947; Q9GZV5;
1-231
100.0MG;CL;
Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ136 Heteromer
P03372; P31947;
1-231
100.00AW;MG;CL;BME;
Fragment AZ-005 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CA;KM2;
14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CA;CL;NA;
Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma st… Heteromer
P03372; P31947;
1-231
100.0MG;NE5;
14-3-3sigma in complex with BLNKpT152 phosphopeptide crystal structure Heteromer
P31947; Q8WV28;
1-231
100MG;
Fragment AZ-018 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0K5Z;CA;
Fragment AZ-021 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;GOL;K6W;
Fragment AZ-023 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100MG;CL;K6T;
Fragment AZ-022 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;GOL;K6Z;
Fragment AZ-006 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100MG;CL;GOL;JT2;
Fragment AZ-016 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;K8W;
Fragment AZ-006 binding at the TAZpS89/14-3-3 sigma interface Heteromer
P31947; Q9GZV5;
1-231
100JT2;
Fragment AZ-019 binding at the TAZpS89/14-3-3 sigma interface Heteromer
P31947; Q9GZV5;
1-231
100KDK;CA;NA;
Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide Heteromer
P31947; P61587;
1-231
100CL;MG;FAR;
14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide Heteromer
P31947; P46937;
1-231
100CA;CL;
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilisator Fusicoccin A Heteromer
P31947; Q9NPC2;
1-231
100FSC;CL;CA;MG;
Fragment AZ-013 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100MG;CL;LJW;
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer Fu… Heteromer
P31947; Q9NPC2;
1-231
99.13FW1;CL;MG;
Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer 16-O-Me-FC-H Heteromer
P31947; Q9NPC2;
1-231
100.00V4;MG;
14-3-3 sigma with AS160 binding site pT642 Heteromer
O60343; P31947;
1-231
100.0NHE;MG;
Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS214 Heteromer
P10636; P31947;
1-231
100.0CL;MG;CA;GOL;
14-3-3 sigma in complex with FOXO1 pS256 peptide Heteromer
P31947; Q12778;
1-231
100.0GOL;B3P;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1008 Heteromer
P31947; Q13526;
1-231
100.0UFH;CA;CL;
14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1011 Heteromer
P31947; Q13526;
1-231
100.0TLQ;CA;CL;NA;
Fragment AZ-001 binding at the p53pT387/14-3-3 sigma interface and additional sites Heteromer
P04637; P31947;
1-231
100.0MG;CL;KTW;GOL;CA;
Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ178 Heteromer
P31947; Q4VCS5;
1-231
100.00B7;MG;
Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (LBD) phosphopeptide Heteromer
P31947; P62508;
1-231
100MG;
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide Heteromer
P31947; Q9NPC2;
1-231
99.13CL;MG;
14-3-3sigma in complex with a TASK3 peptide stabilized by semi-synthetic natural product FC-NAc Heteromer
P31947; Q9NPC2;
1-231
100.0EZ5;CL;NA;
14-3-3 Sigma in complex with phosphorylated (pS210) Gab2 peptide Heteromer
P31947; Q9UQC2;
1-231
100.0MG;
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 22 Heteromer
P31947; Q4VCS5;
1-231
100.0K92;CL;
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer FC… Heteromer
P31947; Q9NPC2;
1-231
99.13FC7;CL;MG;
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fu… Heteromer
P31947; Q9NPC2;
1-231
99.13FJA;MG;CL;
Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fu… Heteromer
P31947; Q9NPC2;
1-231
99.13FC7;MG;CA;CL;
Small molecule stabilizer for 14-3-3/ChREBP (Cmd 43) Heteromer
P31947; Q9NP71;
1-231
100MG;UH9;
Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide and stabilizer Fusicoccin-A Heteromer
P06748; P31947;
1-231
100FSC;CL;
Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif I Heteromer
P31947; Q6TGC4;
1-231
100.0
Fragment AZ-004 binding at the TAZpS89/14-3-3 sigma interface Heteromer
P31947; Q9GZV5;
1-231
100.0L1T;
Fragment AZ-019 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
1-231
100.0MG;CL;GOL;KDK;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045 Heteromer
P31947; Q04206;
1-231
100.0CL;V1H;MG;
Crystal structure of C-terminal modified Tau peptide-hybrid 3.2e with 14-3-3sigma Heteromer
P10636; P31947;
1-231
100.0CA;CL;NA;60H;
Structure of 14-3-3 isoform sigma in complex with a C-Raf1 peptide and a stabilizing small molecule… Heteromer
P04049; P31947;
1-231
100.0M1T;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178 Heteromer
P31947; Q04206;
1-231
100.0CL;V4K;CA;GOL;
Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide and … Heteromer
P31947; P61587;
1-231
100FSC;MG;CL;FAR;
SARS-CoV-2 Nucleocapsid phosphopeptide 193-200 bound to human 14-3-3 sigma Heteromer
P0DTC9; P31947;
1-231
100.0PEG;GOL;BR;TRS;
14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface Heteromer
P03372; P31947;
1-231
100MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027 Heteromer
P31947; Q04206;
1-231
100CL;L3V;CA;MG;
Small molecule stabilizer for 14-3-3/ChREBP (Cmd 42) Heteromer
P31947; Q9NP71;
1-231
100MG;XSL;
14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface Heteromer
P03372; P31947;
1-231
100FSC;
Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide and stabilizer Fusicoccin-A Heteromer
P31947; Q9BWG4;
1-231
100.0FSC;CL;MG;
Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Co… Heteromer
P31947; Q9NPC2;
1-231
99.09CW7;MG;
14-3-3 sigma in complex with hDMX-342+367 peptide Heteromer
O15151; P31947;
1-231
100.0B3P;
14-3-3 sigma in complex with hDMX-367 peptide Heteromer
O15151; P31947;
1-231
100.0SO4;
Henipavirus W protein interacts with 14-3-3 to modulate host gene expression Heteromer
P0C1C7; P31947;
1-231
100CA;
Structure of 14-3-3 sigma delta C with electrophilic peptide 3MHR-5 Heteromer
P31947; P46937;
1-231
100.0TJI;MG;CL;
Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 12 Heteromer
P31947; Q4VCS5;
1-231
100.0K7Q;CA;CL;MG;
14-3-3 sigma in complex with FOXO1 pT24 peptide Heteromer
P31947; Q12778;
1-231
100.0B3P;GOL;
Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide and stabilizer Fusicoccin-A Heteromer
O43353; P31947;
1-231
100.0FSC;MG;CL;
Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptor alpha phosphopepti… Heteromer
P03372; P31947;
1-231
100.0MG;PJN;
Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ176 Heteromer
P31947; P46527;
1-231
100.00HP;MG;CL;
Human 14-3-3 sigma CLU3 mutant complexed with short HSPB6 phosphopeptide Heteromer
O14558; P31947;
1-231
99.56TRS;
Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma st… Heteromer
P03372; P31947;
1-231
100.0NJW;
Engineered conjugation of lysine-specific molecular tweezers with ExoS derived peptidic inhibitor e… Heteromer
G3XDA1; P31947;
1-231
100.0TWZ;NA;GOL;
Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptoralpha phosphopeptid… Heteromer
P03372; P31947;
1-231
100.0MG;8CQ;
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 96h incubation Heteromer
P31947; Q9UQC2;
1-231
100.0MG;
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 48h incubation Heteromer
P31947; Q9UQC2;
1-231
100MG;
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 24h incubation Heteromer
P31947; Q9UQC2;
1-231
100MG;
14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 1h incubation Heteromer
P31947; Q9UQC2;
1-231
100.0MG;
Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-195 Heteromer
P31947; P49675;
1-231
98.7
SARS-CoV-2 Nucleocapsid phosphopeptide 201-210 bound to human 14-3-3 sigma Heteromer
P0DTC9; P31947;
1-231
98.67CL;
Human 14-3-3 sigma fused to the AANAT peptide including phosphoserine-205 Heteromer
P31947; Q16613;
1-231
99.13
CH2 chimera of human 14-3-3 sigma with the Gli1 phosphopeptide around Ser640 Heteromer
P08151; P31947;
1-231
99.56SO4;TRS;
CH3 chimera of human 14-3-3 sigma with the StARD1 peptide including Ser57 Heteromer
P31947; P49675;
1-231
100.0TRS;SO4;
Complex of human 14-3-3 sigma CLU1 mutant with phosphorylated heat shock protein B6 Heteromer
O14558; P31947;
1-231
98.67TRS;NI;
GBP1 bound by 14-3-3sigma Heteromer
P31947; P32455;
1-231
100.0
CryoEM structure of activated CRAF/MEK/14-3-3 complex with NST-628 Heteromer
P04049; P31947; Q02750;
1-231
100.0A1AHE;
Human 14-3-3 sigma complexed with long HSPB6 phosphopeptide Heteromer
O14558; P31947;
2-231
100
CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with swapped phos…homo-4-mer1-231
100.0PEG;
The crystal structure of 14-3-3-sigma at 2.8 angstrom resolutionhomo-2-mer1-233
100.0
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f…homo-2-mer1-231
99.13MG;GEH;
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide stabilized by…homo-2-mer1-231
100.0FSC;CL;MG;
14-3-3sigma in complex with SHN3pS542 phosphopeptide crystal structurehomo-2-mer1-231
100MG;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.010×MG;CL;GOL;Y04;
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 10homo-2-mer1-231
99.57MG;CL;OQ3;
Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 4homo-2-mer1-231
99.57MG;CL;OQ9;
Ternary structure of 14-3-3sigma, strep-tagged PKA-responsive ERa phosphopeptide, and Fusicoccin-A.homo-2-mer1-231
100.0MG;SIT;
14-3-3sigma bound to strep-tagged PKA-responsive ERa phosphopeptidehomo-2-mer1-231
100MG;
14-3-3sigma bound to PKA-responsive ERa phosphopeptidehomo-2-mer1-231
100MG;
14-3-3 Sigma in complex with phosphorylated ATPase peptidehomo-2-mer1-231
100MG;CA;
14-3-3sigma in complex with SHN3pT869 phosphopeptide crystal structurehomo-2-mer1-231
100MG;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.01CT;GOL;CL;MG;
14-3-3s binding to non-natural peptide 2dhomo-2-mer1-231
100MG;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.02CT;GOL;CL;MG;
Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide inhibited by semi-s…homo-2-mer1-231
100.0HY5;TPO;CL;NA;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.010×MG;CL;GOL;0KH;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.0MG;CL;GOL;0KB;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.0MG;CL;GOL;Y09;
Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f…homo-2-mer1-231
99.13MG;GF8;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.0MG;CL;GOL;Y03;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.010×MG;CL;GOL;Y06;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.010×MG;CL;GOL;Y07;
Small-molecule inhibitor of 14-3-3 protein-protein interactionshomo-2-mer1-231
100MG;OO8;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.0MG;CL;GOL;0KG;
Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screeninghomo-2-mer1-231
100.0MG;CL;GOL;0KC;
Covalent attachment of pyridoxal-phosphate derivatives to 14-3-3 proteinshomo-2-mer1-231
100.0MG;CL;GOL;
14-3-3s binding to non-natural peptide 2chomo-2-mer1-231
100MG;
Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptidehomo-2-mer1-231
100CL;MG;
Binary complex of 14-3-3 sigma and a high-affinity non-canonical 9-mer peptide binderhomo-2-mer1-231
100MG;CL;
Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide and stabilizing Fusicoccin Ahomo-2-mer1-231
100.0FSC;MG;CL;
Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-57homo-2-mer1-231
99.56PGE;IMD;
14-3-3 in complex with Pyrin pS208homo-2-mer1-231
100.0MG;
Structure of 14-3-3 sigma delta C with electrophilic peptide 4IEA-5homo-2-mer1-231
100.0TJI;MG;CL;
Molecular tweezers modulate 14-3-3 protein-protein interactions.homo-2-mer1-231
100.09SZ;CL;GOL;
Ligand-free state of human 14-3-3 sigma isoformhomo-2-mer1-231
100.0PEG; 12×SO4;
Crystal structure of the human sigma isoform of 14-3-3 in complex with a mode-1 phosphopeptidehomo-2-mer1-231
100.0CA;
14-3-3 sigma complexed with a phosphorylated 16E6 peptidehomo-2-mer1-231
98.7TAR;
human 14-3-3 sigma isoform in complex with IMPhomo-2-mer1-231
100.0IMP;SO4;
Human 14-3-3 sigma isoform in complex with PLPhomo-2-mer1-231
100.0PLP;SO4;
Molecular tweezers modulate 14-3-3 protein-protein interactionshomo-2-mer1-231
100.09SZ;CL;
CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with self-bound p…homo-2-mer1-231
99.5511×CD;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5iqp.1.Ahomo-2-mer0.831-232
70.49